Supernus Pharmaceuticals   Report issue

Contributed to NME For profit Phase 2 Phase 3 Phase 4
Founded: Rockville MD United States (2005)

Organization Overview

First Clinical Trial
2008
NCT00626236
First Marketed Drug
2005
apomorphine (apokyn)
First NDA Approval
2021
viloxazine (Qelbree)
Last Known Activity
2024

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

MDD US | Supernus Pharmaceuticals | Supernus Pharmaceuticals, Inc. | SUPERNUS PHARMS

Active Ingredients

Marketed Drugs (5)

apomorphine (apokyn) (2004)

oxcarbazepine (trileptal) (2012)

safinamide (xadago) (2017)

topiramate (topamax) (2013)

viloxazine (Qelbree) (2021 NDA)

Drugs in Phase 4 Trials (3)

Key: Supernus Pharmaceuticals (2) Acquired (1)

amantadine (symmetrel) (9 trials)

topiramate (topamax) (4 trials)

viloxazine (Qelbree) (13 trials)

Drugs in Phase 3 Trials (4)

molindone (moban) (7 trials)

oxcarbazepine (trileptal) (4 trials)

rimabotulinumtoxinB (Myobloc) (2 trials)

spn-810 (2 trials)

Drugs in Phase 2 Trials (3)

Key: Supernus Pharmaceuticals (1) Acquired (2)

huperzine a (4 trials)

nv-5138 (3 trials)

oseltamivir (tamiflu) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Aggression (Phase 3)

Attention Deficit Disorder with Hyperactivity (Phase 3)

Conduct Disorder (Phase 2)

Disease (Phase 4)

Epilepsies, Partial (Phase 3)

Epilepsy (Phase 3)

Headache (Phase 4)

Headache Disorders (Phase 4)

Hyperkinesis (Phase 3)

Impulsive Behavior (Phase 2)

Migraine Disorders (Phase 4)

Seizures (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 48
  • # of Trial APIs: 10